ARCT Relative Valuation
ARCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARCT is overvalued; if below, it's undervalued.
Historical Valuation
Arcturus Therapeutics Holdings Inc (ARCT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.49. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.83
Fair
-2.71
PE
1Y
3Y
5Y
Trailing
Forward
-0.31
EV/EBITDA
Arcturus Therapeutics Holdings Inc. (ARCT) has a current EV/EBITDA of -0.31. The 5-year average EV/EBITDA is -2.28. The thresholds are as follows: Strongly Undervalued below -8.96, Undervalued between -8.96 and -5.62, Fairly Valued between 1.06 and -5.62, Overvalued between 1.06 and 4.40, and Strongly Overvalued above 4.40. The current Forward EV/EBITDA of -0.31 falls within the Historic Trend Line -Fairly Valued range.
-0.38
EV/EBIT
Arcturus Therapeutics Holdings Inc. (ARCT) has a current EV/EBIT of -0.38. The 5-year average EV/EBIT is -12.41. The thresholds are as follows: Strongly Undervalued below -92.06, Undervalued between -92.06 and -52.24, Fairly Valued between 27.41 and -52.24, Overvalued between 27.41 and 67.24, and Strongly Overvalued above 67.24. The current Forward EV/EBIT of -0.38 falls within the Historic Trend Line -Fairly Valued range.
4.31
PS
Arcturus Therapeutics Holdings Inc. (ARCT) has a current PS of 4.31. The 5-year average PS is 9.72. The thresholds are as follows: Strongly Undervalued below -29.51, Undervalued between -29.51 and -9.90, Fairly Valued between 29.33 and -9.90, Overvalued between 29.33 and 48.95, and Strongly Overvalued above 48.95. The current Forward PS of 4.31 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Arcturus Therapeutics Holdings Inc. (ARCT) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.40. The thresholds are as follows: Strongly Undervalued below -41.56, Undervalued between -41.56 and -20.58, Fairly Valued between 21.38 and -20.58, Overvalued between 21.38 and 42.37, and Strongly Overvalued above 42.37. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Arcturus Therapeutics Holdings Inc. (ARCT) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.14. The thresholds are as follows: Strongly Undervalued below -17.85, Undervalued between -17.85 and -10.49, Fairly Valued between 4.22 and -10.49, Overvalued between 4.22 and 11.57, and Strongly Overvalued above 11.57. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Arcturus Therapeutics Holdings Inc (ARCT) has a current Price-to-Book (P/B) ratio of 0.83. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately -62.86% higher. Relative to its 5-year average P/B ratio of 2.72, the current P/B ratio is about -69.59% higher. Arcturus Therapeutics Holdings Inc (ARCT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.75%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.11% , the current FCF yield is about -100.00% lower.
0.83
P/B
Median3y
2.23
Median5y
2.72
-31.32
FCF Yield
Median3y
-4.75
Median5y
-10.11
Competitors Valuation Multiple
The average P/S ratio for ARCT's competitors is 0.00, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -58.84%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ARCT decreased by 59.75% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -16.56 to -78.41.
The secondary factor is the Revenue Growth, contributed -58.84%to the performance.
Overall, the performance of ARCT in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Arcturus Therapeutics Holdings Inc (ARCT) currently overvalued or undervalued?
What is Arcturus Therapeutics Holdings Inc (ARCT) fair value?
How does ARCT's valuation metrics compare to the industry average?
What is the current P/B ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Dec 05 2025?
What is the current FCF Yield for Arcturus Therapeutics Holdings Inc (ARCT) as of Dec 05 2025?
What is the current Forward P/E ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Dec 05 2025?